retapamulin
Sign in to saveAlso known as SB-275833, {(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl} 2-({(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl}sulfanyl)acetate
Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It is the first drug in the new class of pleuromutilin antibiotics to be approved for human use. It is marketed as an ointment under the brand names Altabax and Altargo.
~3 min read
Encyclopedic overview
7 sectionsContents
- Indications
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Contraindications
- Adverse reactions
- References
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 464381219 | IUPAC_name = (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro-3a,9-propano-3aH-cyclopenta[8]annulen-8-yl{[(1R,3s,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]sulfanyl}acetate | image = Retapamulin.svg | image_class = skin-invert-image | image2 = Retapamulin 3D sticks.png | image_class2 = bg-transparent
| tradename = Altabax, Altargo | Drugs.com = | MedlinePlus = a607049 | licence_EU = yes | licence_US = Retapamulin | pregnancy_AU = | pregnancy_US = B | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = POM | legal_US = Rx-only | legal_status = | routes_of_administration = Topical (ointment)
Excerpted from Wikipedia’s “retapamulin” article, available under the CC BY-SA 4.0 licence.